The following represents disclosure information provided by authors of this abstract. The ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer Planning Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Trastuzumab-reactive antibodies (TR-abs) in serum and trastuzumab (Tzb) benefit prediction in patients with HER2-overexpressing breast cancer.
Paula Raffin Pohlmann
No relevant relationships to disclose
Todd W. Miller
No relevant relationships to disclose
David L Blum
No relevant relationships to disclose
Dipti Pareh
No relevant relationships to disclose
Heping Yan
No relevant relationships to disclose
Cammie R Sutton
No relevant relationships to disclose
Teresa C Dugger
No relevant relationships to disclose
Lupe G Salazar
No relevant relationships to disclose
William Wu
No relevant relationships to disclose
Michelle L. Reyzer
No relevant relationships to disclose
Mary L. Disis
Consultant or Advisory Role - Bristol-Myers Squibb; EMD Serono; Immunovaccine; Roche; VentiRx
Stock Ownership - Epigenomics; VentiRx
Research Funding - GlaxoSmithKline
Ray Mernaugh
No relevant relationships to disclose
Carlos L. Arteaga
No relevant relationships to disclose